ESR1 and uterine cancer: Another complication with the use of estrogen therapies for post-menopausal people with AD is that they can increase risks of breast and uterine cancer due to the cell proliferative effects of estrogen receptor alpha (ERα) (Ali and Coombes, 2000; Péqueux et al., 2012; Shete et al., 2023).